[Federal Register Volume 70, Number 99 (Tuesday, May 24, 2005)]
[Notices]
[Pages 29769-29770]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-10316]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Treatment of Human Viral Infections (Resveratrol)

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
U.S. Provisional Application No. 60/588,013 filed 13 Jul 2004 (DHHS 
Reference No. E-279-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; [email protected].

    This application describes the methods for treating or preventing 
an HIV infection by the administration of an Egr 1 activator called 
Resveratrol (3, 5, 4''-trihydroxystilbene) and its derivatives. It has 
been known that HIV, once it infects a cell, integrates into the 
cellular genome and can (1) rapidly undergo lytic infection, or (2) lay 
dormant for a period of time (latent infection). The existence of 
latent infected cells poses a great challenge to HIV therapy because 
(1) there are no good existing means that can separate the latent 
infected cells from the uninfected cells; (2) even when antiretroviral 
drugs are able to completely suppress detectable HIV replication, these 
latent infected cells will remain and HIV can subsequently complete the 
viral replication cycle to produce more virus. Since Resveratrol and 
its derivatives can activate lytic replication from latent infected 
cells via its effects on Erk1/2 signaling, Resveratrol and its 
derivatives may lead to therapies in which Resveratrol and/or its 
derivatives is given together with highly active antiretroviral therapy 
in an effort to decrease or eliminate the reservoir of latent infected 
cells with hope of perhaps eventually curing a patient of HIV 
infection.

Treatment of Human Viral Infections (Proteosome Inhibitors)

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
U.S. Provisional Application No. 60/587,810 filed 13 Jul 2004 (DHHS 
Reference No. E-280-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; [email protected].

    This application describes the methods for treating or preventing 
an HIV infection by the administration of proteosome inhibitors and 
their derivatives. It has been known that HIV, once it infects a cell, 
integrates into the cellular genome and can (1) rapidly undergo lytic 
infection, or (2) lay dormant for a period of time (latent infection). 
The existence of latent infected cells poses a great challenge to HIV 
therapy because (1) there are no good existing means that can separate

[[Page 29770]]

the latent infected cells from the uninfected cells; (2) even when 
antiretroviral drugs are able to completely suppress detectable HIV 
replication, these latent infected cells will remain and HIV can 
subsequently complete the viral replication cycle to produce more 
virus. Since proteosome inhibitors can activate lytic replication from 
latent infected cells, proteosome inhibitors may lead to therapies in 
which proteosome inhibitors are given together with highly active 
antiretroviral therapy in an effort to decrease or eliminate the 
reservoir of latent infected cells with hope of perhaps eventually 
curing a patient of HIV infection.

Treatment of Human Viral Infections (Imatinib)

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
U.S. Provisional Application No. 60/588,015 filed 13 Jul 2004 (DHHS 
Reference No. E-281-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; [email protected].

    This application describes the methods for treating or preventing a 
HIV infection by the administration of abl-kinase inhibitor called 
imatinib and its derivatives. Several available agents can inhibit HIV 
replication by targeting one or another viral protein, such as the 
viral reverse transcriptase, protease, envelope fusion process, or 
integrase, or by targeting the interaction of a viral component with a 
host cell component, for example the host cell viral receptor or co-
receptor. However, HIV can readily become resistant to these drugs, and 
new therapeutic approaches for HIV infection are needed. The studies 
described in the application show that the expression of many host cell 
genes changes in response to HIV replication, and show that targeting 
one of these changes with imatinib can inhibit viral replication. Thus 
targeting the host cell, and making the host cell less hospitable to 
the virus can inhibit viral replication. The application thus describes 
a new agent that inhibits viral replication by acting on the host cell, 
which may offer new approaches to therapy for HIV infection. These 
approaches may be less likely to engender rapid resistance in the virus 
to the therapy.

Treatment of Human Viral Infections (Farnesyl Transferase Inhibitors)

Drs. Steven Zeichner and Vyjayanthi Krishnan (NCI).
U.S. Provisional Application No. 60/587,771 filed 13 Jul 2004 (DHHS 
Reference No. E-282-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; [email protected].

    This application describes the methods for treating or preventing 
an HIV infection by the administration of farnesyl transferase 
inhibitors such as FTI277, L-744832, BMS214662, R115777 and SCH66336. 
It has been known that HIV, once it infects a cell, integrates into the 
cellular genome and can (1) rapidly undergo lytic infection, or (2) lay 
dormant for a period of time (latent infection). The existence of 
latent infected cells poses a great challenge to HIV therapy because 
(1) there are no good existing means that can separate the latent 
infected cells from the uninfected cells; (2) even when antiretroviral 
drugs are able to completely suppress detectable HIV replication, these 
latent infected cells will remain and HIV can subsequently complete the 
viral replication cycle to produce more virus. Since farnesyl 
transferase inhibitors can activate lytic replication from latent 
infected cells by modulating membrane-bound Ras-Rho levels, farnesyl 
transferase inhibitors may lead to therapies in which farnesyl 
transferase inhibitor is given together with highly active 
antiretroviral therapy in an effort to decrease or eliminate the 
reservoir of latent infected cells with hope of perhaps eventually 
curing a patient of HIV infection.

    Dated: May 17, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-10316 Filed 5-23-05; 8:45 am]
BILLING CODE 4140-01-P